Semaglutide(Hybio Pharma)

司美格鲁肽（深圳翰宇）

Report date: 2026/04/22 20:01:10

Base Information

Drug NameSemaglutide(Hybio Pharma)
Drug Alias Name司美格鲁肽注射液（预填充注射笔）HY310HY-310
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Cardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHybio Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active Companies3sbio IncHybio Pharmaceutical Co LtdZhejiang Wansheng Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus, Type 2Cardiovascular Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A